PYRIDONE COMPOUND

20100179137

12/663246

June 06, 2008

[Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.

Kamikubo, Takashi (Tokyo, JP); Hirayama, Fukushi (Tokyo, JP); Miura, Masanori (Tokyo, JP); Komiya, Yuriko (Tokyo, JP); Okuda, Takao (Tokyo, JP); Maki, Keisuke (Tokyo, JP)

1. A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [chemical expression included] [wherein Ring A represents aryl or heteroaryl, X1, and X2 are the same as or different from each other, and represent a single bond, —O—, or —S—, L1 represents lower alkylene which may be substituted, L2 represents lower alkylene or lower alkenylene, which may be each substituted, R1 represents R6 or a group represented by the following formula (II): [chemical expression included] Ring B represents aryl or heteroaryl, R6 represents —CO2R0, —CN, —C(O)—N(R0)—S(O)2—R8, —C(O)—N(R0)—S(O)2—N(R0)—R8, —N(R0)—C(O)—N(R0)—S(O)2—R8, —C(O)—N(R0)—R8, or a group represented by the following formula (III) or (IV): [chemical expression included] or a group represented by any one of the following formulae (V) to (XIV): [chemical expression included] R0 are the same as or different from each other, and represent H or lower alkyl, R8 represents H, lower alkyl, halogeno-lower alkyl, cycloalkyl, -(lower alkylene)-OR0, -(lower alkylene)-O—C(O)—R0, or -(lower alkylene)-CO2R0, J represents a single bond, lower alkylene, or lower alkenylene, R2 and R7 are the same as or different from each other, and represent lower alkyl, halogen, cyano, nitro, halogeno-lower alkyl, —OR0, —O-(halogeno-lower alkyl), —O—(cycloalkyl), —O-(lower alkylene)-OR0, —N(R0)2, morpholyl, -(lower alkylene)-OR0, -(lower alkenylene)-R0, or —O—C(O)—R0, m and n are the same as or different from each other, and represent an integer of 0 to 3, R3, R4, and R5 are the same as or different from each other, and represent H, halogen, —CN, lower alkyl, lower alkenyl, cycloalkyl, halogeno-lower alkyl, —OR0, —O-halogeno-lower alkyl, —CO2R0, —S(O)2R0, or —C(O)N(R0)2, provided that methyl{6-[(3-methylphenoxy)methyl]-2-oxopyridin-1(2H)-yl}acetate is excluded].

2. The compound or a pharmaceutically acceptable salt thereof as described in claim 1, wherein Ring A is phenyl, —X1-L2-X2— is a group selected from the group consisting of lower alkylene, lower alkenylene, -(lower alkylene)-O—, and -(lower alkylene)-S—, R1 is a group represented by the formula (II), R4 is H, R3 and R5 are each the same as or different from each other, and represent H, Cl, Br, or cyclopropyl, Ring B is phenyl, J is a single bond, and R6 is —CO2H.

3. A compound selected from the group consisting of: 4-(2-{3,5-dichloro-6-[(3-isopropylphenoxy)methyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-6-[2-(2-ethoxyphenyl)ethyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-6-[(E)-2-(3-isopropylphenyl)vinyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-{2-[3,5-dichloro-2-oxo-6-{(E)-2-[2-(trifluoromethoxy)phenyl]vinyl}pyridin-1(2H)-yl]ethyl}benzoic acid, 4-{2-[3,5-dichloro-2-oxo-6-{(E)-2-[2-(trifluoromethoxy)phenyl]ethyl}pyridin-1(2H)-yl]ethyl}benzoic acid, 4-(2-{3,5-dichloro-2-oxo-6-[(3-propyl phenoxy)methyl]pyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-6-[(2-isopropoxyphenoxy)methyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-2-oxo-6-[(E)-2-(3-propoxyphenyl)vinyl]pyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3-chloro-5-cyclopropyl-6-[(3-ethylphenoxy)methyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-{2-[3-chloro-5-cyclopropyl-2-oxo-6-{(E)-2-[3-(trifluoromethoxy)phenyl]vinyl}pyridin-1(2H)-yl]ethyl}benzoic acid, 4-{2-[3-chloro-5-cyclopropyl-2-oxo-6-{2-[3-(trifluoromethoxy)phenyl]ethyl}pyridin-1(2H)-yl]ethyl}benzoic acid, 4-(2-{5-bromo-6-[(E)-2-(3-ethylphenyl)vinyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{5-chloro-6-[(E)-2-(3-ethylphenyl)vinyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, and 4-{2-[5-chloro-2-oxo-6-{(E)-2-[3-(trifluoromethoxy)phenyl]vinyl}pyridin-1(2H)-yl]ethyl}benzoic acid, or a pharmaceutically acceptable salt thereof.

4. A compound selected from the group consisting of: 4-(2-{3,5-dichloro-6-[(E)-2-(3-methoxyphenyl)vinyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-6-[(3-ethylphenoxy)methyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-2-oxo-6-({[3-(trifluoromethoxy)phenyl]sulfanyl}methyl)pyridin-1(2H)-yl]ethyl}benzoic acid, 4-{2-[3,5-dichloro-2-oxo-6-{2-[3-(trifluoromethoxy)phenyl]ethyl}pyridin-1(2H)-yl]ethyl}benzoic acid, 4-{2-[5-bromo-2-oxo-6-{(E)-2-[3-(trifluoromethoxy)phenyl]vinyl}pyridin-1(2H)-yl]ethyl}benzoic acid, 4-(2-{5-bromo-6-[(E)-2-(3-ethylphenyl)vinyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-6-[(2-ethoxyphenoxy)methyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-(2-{3,5-dichloro-6-[(E)-2-(3-ethylphenyl)vinyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, 4-{2-[3,5-dichloro-2-oxo-6-{(E)-2-[3-(trifluoromethoxy)phenyl]vinyl}pyridin-1(2H)-yl]ethyl}benzoic acid, and 4-(2-{3,5-dichloro-6-[(E)-2-(3-ethoxyphenyl)vinyl]-2-oxopyridin-1(2H)-yl}ethyl)benzoic acid, or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof as described in claim 1, and a pharmaceutically acceptable excipient.

6. A pharmaceutical composition for preventing or treating peripheral arterial occlusive disease, comprising the compound or a pharmaceutically acceptable salt thereof as described in claim 1.

7. Use of the compound or a pharmaceutically acceptable salt thereof as described in claim 1 for the manufacture of an agent for preventing or treating peripheral arterial occlusive disease.

8. A method for preventing or treating peripheral arterial occlusive disease, comprising administering to a patient an effective amount of the compound or a pharmaceutically acceptable salt thereof as described in claim 1.

5142/278

61; 07; 61; 07; 07; 61; 07; 07; 61; 61; 07; 07; 61; 07; 61; 61

edspap.20100179137